Medi Caps , a pharmaceutical company with diversified interests in real estate, has announced its unaudited financial results for the second quarter and first half of the fiscal year 2025-26. The company's performance shows a mixed picture across its various business segments.

Revenue and Profitability

For the quarter ended September 30, 2025, Medi-Caps Limited reported:

• Consolidated revenue from operations: Rs. 268.76 crore (down from Rs. 829.62 crore in Q2 FY2025)
• Total income: Rs. 302.25 crore (compared to Rs. 858.24 crore in Q2 FY2025)
• Consolidated profit before tax: Rs. 182.15 crore (up from Rs. 31.23 crore in Q2 FY2025)

Notably, this represents a recovery from the loss of Rs. 349.19 crore reported in Q1 FY2026.

Segment Performance

Medi-Caps Limited operates in two reportable segments:

1. Pharma Division
2. Real Estate Division

The Real Estate Division generated revenue of Rs. 99.78 lakh from the sale of shops at Medi-caps Business Park during the quarter under review.

Financial Position

As of September 30, 2025, the company's consolidated financial position shows:

Cash Flow and Liquidity

The consolidated cash flow statement for the half-year ended September 30, 2025, indicates:

• Net cash flow from operating activities: Rs. (158.95) lakh
• Net cash used in investing activities: Rs. 126.81 lakh
• Net decrease in cash and cash equivalents: Rs. (32.14) lakh

Subsidiary Performance

The consolidated results include the performance of Medgel Private Limited, a wholly-owned subsidiary. For the quarter ended September 30, 2025, Medgel Private Limited reported:

• Total assets: Rs. 2,566.22 lakh
• Total income: Rs. 101.25 lakh
• Net loss after tax: Rs. (210.80) lakh
• Total comprehensive income: Rs. (286.58) lakh

Management Commentary

The company's Board of Directors reviewed and approved these unaudited financial results in their meeting held on November 12, 2025. The management has exercised due diligence to ensure that the financial results provide a true and fair view of the company's affairs.

Conclusion

Medi-Caps Limited's financial performance for Q2 and H1 FY2026 reflects challenges in its core pharmaceutical business, while its real estate division has shown some positive momentum. The significant year-over-year decline in revenue and the fluctuating profitability underscore the need for close monitoring of the company's strategic initiatives and market conditions in the coming quarters.

Investors and stakeholders should note that these are unaudited results and may be subject to changes upon final audit.

Medi Caps Limited , a pharmaceutical company, has reported its financial results for the first quarter, ending June 30. The company faced significant challenges during this period, with both standalone and consolidated financials showing losses.

Standalone Financial Performance

On a standalone basis, Medi Caps Limited reported:

• No revenue from operations for the quarter, compared to Rs 29.02 lakhs in the same quarter of the previous year
• A net loss of Rs 39.75 lakhs, contrasting with a profit of Rs 33.17 lakhs in the corresponding quarter last year
• Other income of Rs 31.33 lakhs, up from Rs 10.72 lakhs in the previous year's quarter

Consolidated Financial Results

The consolidated financial results, including the performance of its wholly-owned subsidiary Medgel Private Limited, are as follows:

The consolidated revenue from operations decreased by 56.61% year-over-year to Rs 268.76 lakhs. The company's net loss widened significantly to Rs 349.19 lakhs, compared to a loss of Rs 57.10 lakhs in the same quarter of the previous fiscal year.

Segment Performance

Medi Caps Limited operates in two segments:

1. Pharma Division: Generated revenue of Rs 268.76 lakhs but reported a segment loss of Rs 308.14 lakhs before tax and interest.
2. Real Estate Division: Did not generate any revenue and reported a loss of Rs 39.75 lakhs before tax and interest.

Corporate Actions and Board Decisions

The Board of Directors, in their meeting held on August 5, made several key decisions:

1. Annual General Meeting: The 42nd Annual General Meeting (AGM) is scheduled for September 18, to be held through Video Conferencing or Other Audio-Visual Means.

2. Appointment of Secretarial Auditor: Joshi Sahay and Company, Practicing Company Secretaries, have been appointed as the Secretarial Auditor for a period of five consecutive years, subject to shareholder approval at the upcoming AGM.

3. Re-appointment of Independent Director: Mr. Dharmendra Solanki has been re-appointed as a Non-Executive Independent Director for a second term of five years, subject to shareholder approval at the AGM.

Conclusion

The significant decline in revenue and widening losses indicate challenging market conditions for Medi Caps Limited, particularly in its pharmaceutical operations. Investors and stakeholders will be keenly watching the company's performance in the coming quarters for signs of recovery and the impact of any strategic initiatives to improve financial results.

Shareholders and interested parties can access the detailed financial results on the company's website at www.medicaps.com and on the BSE website at www.bseindia.com .